These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27905011)

  • 1. Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data.
    Armstrong AW; Koning JW; Rowse S; Tan H; Mamolo C; Kaur M
    Dermatol Ther (Heidelb); 2017 Mar; 7(1):97-109. PubMed ID: 27905011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States.
    Armstrong AW; Koning JW; Rowse S; Tan H; Mamolo C; Kaur M
    Clin Drug Investig; 2017 May; 37(5):493-501. PubMed ID: 28303523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
    Feldman SR; Evans C; Russell MW
    J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Claims Analyses of Comorbidity Burden, Treatment Pattern, Healthcare Resource Utilization, and Costs in Pediatric Psoriasis.
    Edson-Heredia E; Anderson S; Guo J; Zhu B; Malatestinic WN; Wine-Lee L; Swanson E
    Adv Ther; 2021 Jul; 38(7):3948-3961. PubMed ID: 34091866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.
    Armstrong AW; Robertson AD; Wu J; Schupp C; Lebwohl MG
    JAMA Dermatol; 2013 Oct; 149(10):1180-5. PubMed ID: 23945732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.
    Armstrong AW; Foster SA; Comer BS; Lin CY; Malatestinic W; Burge R; Goldblum O
    BMC Dermatol; 2018 Jun; 18(1):4. PubMed ID: 29954363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis.
    Paller AS; Singh R; Cloutier M; Gauthier-Loiselle M; Emond B; Guérin A; Ganguli A
    J Drugs Dermatol; 2018 Feb; 17(2):187-194. PubMed ID: 29462227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting.
    Gulliver WP; Randell S; Gulliver S; Gregory V; Nagle S; Chambenoit O
    J Cutan Med Surg; 2018; 22(6):567-576. PubMed ID: 29952225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns among patients with psoriasis using a large national payer database in the United States: a retrospective study.
    Murage MJ; Kern DM; Chang L; Sonawane K; Malatestinic WN; Quimbo RA; Feldman SR; Muram TM; Araujo AB
    J Med Econ; 2018 Oct; ():1-9. PubMed ID: 30358465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics for the primary care physician: Review and treatment of psoriasis.
    Schadler ED; Ortel B; Mehlis SL
    Dis Mon; 2019 Mar; 65(3):51-90. PubMed ID: 30037762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey.
    Armstrong AW; Jayade S; Rege S; Joshi N; Patel V; Kalirai S; Wolin D; Boyle K; Patel D; Seigel L
    Dermatol Ther (Heidelb); 2024 Feb; 14(2):421-439. PubMed ID: 38252376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
    Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
    J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center.
    Au SC; Madani A; Alhaddad M; Alkofide M; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):861-6. PubMed ID: 23986158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey.
    Horn EJ; Fox KM; Patel V; Chiou CF; Dann F; Lebwohl M
    J Am Acad Dermatol; 2007 Dec; 57(6):957-62. PubMed ID: 17706322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
    Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans.
    Feldman SR; Wu JJ; Rastogi S; Menges B; Lingohr-Smith M; Lin J
    J Med Econ; 2018 May; 21(5):537-541. PubMed ID: 29357713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing patient copayment levels for topical and systemic treatments in plaque psoriasis as a case for evidence-based, sustainable pharmaceutical policy change in Greece.
    Souliotis K; Golna C; Kani C; Litsa P
    J Med Econ; 2016 Nov; 19(11):1021-1026. PubMed ID: 27207488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearance of psoriasis: the impact of private versus public insurance.
    Buzney CD; Peterman C; Saraiya A; Au SC; Dumont N; Mansfield R; Gottlieb AB
    J Drugs Dermatol; 2015 Feb; 14(2):119-25. PubMed ID: 25689806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Unmet Needs and Treatment Patterns of Paediatric Psoriasis Patients: A Real-World Evidence Study in Spain.
    de Lucas R; Vicente A; Richardson C; Lucas J; Gillespie-Akar L; Gómez-Labrador L; Torrelo A
    Actas Dermosifiliogr; 2023 May; 114(5):T382-T391. PubMed ID: 37088286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.